



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/583,738	05/31/2000	Hossein A. Ghanbari	018792/0180	2794

7590

10/22/2002

Foley & Lardner
Washington Harbour
3000 K Street N W Suite 500
Washington, DC 20007-5109

EXAMINER

PORTNER, VIRGINIA ALLEN

ART UNIT	PAPER NUMBER
----------	--------------

1645

DATE MAILED: 10/22/2002

11

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

09/583,738

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER
	11

DATE MAILED:

Below is a communication from the EXAMINER in charge of this application

COMMISSIONER OF PATENTS AND TRADEMARKS

ADVISORY ACTION

☒ THE PERIOD FOR RESPONSE:

a) ☒ is extended to run 3mo or continues to run _____ from the date of the final rejection

b) ☐ expires three months from the date of the final rejection or as of the mailing date of this Advisory Action, whichever is later. In no event however, will the statutory period for the response expire later than six months from the date of the final rejection.

Any extension of time must be obtained by filing a petition under 37 CFR 1.136(a), the proposed response and the appropriate fee. The date on which the response, the petition, and the fee have been filed is the date of the response and also the date for the purposes of determining the period of extension and the corresponding amount of the fee. Any extension fee pursuant to 37 CFR 1.17 will be calculated from the date of the originally set shortened statutory period for response or as set forth in b) above.

☐ Appellant's Brief is due in accordance with 37 CFR 1.192(a).

☒ Applicant's response to the final rejection, filed 9/5/02 has been considered with the following effect, but it is not deemed to place the application in condition for allowance:

1. ☐ The proposed amendments to the claim and/or specification will not be entered and the final rejection stands because:

- a. ☐ There is no convincing showing under 37 CFR 1.116(b) why the proposed amendment is necessary and was not earlier presented.
- b. ☐ They raise new issues that would require further consideration and/or search. (See Note).
- c. ☐ They raise the issue of new matter. (See Note).
- d. ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal.
- e. ☐ They present additional claims without cancelling a corresponding number of finally rejected claims.

NOTE: _____

2. ☐ Newly proposed or amended claims _____ would be allowed if submitted in a separately filed amendment cancelling the non-allowable claims.

3. ☒ Upon the filing an appeal, the proposed amendment ☒ will be entered ☐ will not be entered and the status of the claims will be as follows:

Claims allowed: none

Claims objected to: none

Claims rejected: 23-33, 35-47, 49-50

However;

☒ Applicant's response has overcome the following rejection(s): Rejections under 35 USC 112, Second paragraph (claims 23, 33-47)

4. ☒ The affidavit, exhibit or request for reconsideration has been considered but does not overcome the rejection because See attached.

5. ☐ The affidavit or exhibit will not be considered because applicant has not shown good and sufficient reasons why it was not earlier presented.

☐ The proposed drawing correction ☐ has ☐ has not been approved by the examiner.

☐ Other

Art Unit: 1645

Response to Remarks

Claims 23-33, 35-47 and 49-50 are pending.

Rejections Withdrawn

1. Claim 23 rejected under 35 U.S.C. 112, second paragraph for reciting the phrases "a bacterial organism" (preamble) and "the bacteriophage preparation consisting of two or more bacteriophage", in light of the amendment of claim 23 to recite the phrase "is specific for the bacterial infection treated".
2. Claims 33 and 47 rejected under 35 U.S.C. 112, second paragraph for the recitation of the phrase "wherein the preparation is resistant to one or more properties selected from the group consisting of" in light of the amendment of claims 33 and 47 to define the bacteriophage preparation is resistant.

Rejections Maintained

3. Claims 23-25, 29-30,33-39,43-44,47-50 rejected under 35 U.S.C. 102(e) as being anticipated by Merrill et al (US Pat 5,688,501; effective filing date of April 5, 1994) .
4. Claims 23-24, 33-34, 37-38, 47-48 rejected under 35 U.S.C. 102(b) as being anticipated by Norris (US Pat. 4,957,686).
5. Claims 26 and 40 rejected under 35 U.S.C. 103(a) as being unpatentable over Merrill et al (US Pat 5,688,501; effective filing date of April 5, 1994) as applied to claims 23-25, 29-30,33-39,43-44,47-50 above, in view of Denney (US Pat. 3,793,151).
6. Claims 27 and 41 rejected under 35 U.S.C. 103(a) as being unpatentable over Merrill et al (US Pat 5,688,501; effective filing date of April 5, 1994) as applied to claims 23-25, 29-30,33-39,43-44,47-50 above, in view of He et al (1992).
7. Claims 28 and 42 rejected under 35 U.S.C. 103(a) as being unpatentable over Merrill et al (US Pat 5,688,501; effective filing date of April 5, 1994) as applied to claims 23-25, 29-30,33-39,43-44,47-50 above, in view of Sekaninova et al (1995).
8. Claims 31 and 45 rejected under 35 U.S.C. 103(a) as being unpatentable over Merrill et al (US Pat 5,688,501; effective filing date of April 5, 1994) as applied to claims 23-25, 29-30,33-39,43-44,47-50 above, in view of Bar-Shalom et al (US Pat. 5,213,808).
9. Claim 45 rejected under 35 U.S.C. 103(a) as being unpatentable over Merrill et al (US Pat 5,688,501; effective filing date of April 5, 1994) as applied to claims 23-25, 29-30,33-39,43-44,47-50 above, in view of Tomalia et al (US Pat. 5,714,166).

Art Unit: 1645

Response To Arguments

10. The rejection of claims 23-25, 29-30,33-39,43-44,47-50 under 35 U.S.C. 102(e) as being anticipated by Merrill et al (US Pat 5,688,501; effective filing date of April 5, 1994) is traversed on the grounds that “wide host range” is specifically defined at page 8, paragraph 1 and page 26, Example 9 to be specific types of phage that are able to kill more bacteria than another, a specific disclosed species being 83A.

11. It is the position of the examiner that at page 8, paragraph 1 and page 26, Example 9, multiple embodiments, definitions, of the phrase “wide host range” could be found. One definition is “[T]he expression “wide host range” denotes a bacteriophage that is capable of killing bacteria from a variety of different hosts.” Clearly the lambda phage of Merrill et al are able to kill bacteria from a variety of different hosts; the reference also claims the utilization of bacteriophages that are genus specific, and thus would infect and kill a plurality of strains and species of each genus of bacteria.

It is also the position of the examiner that Applicant’s arguments are not commensurate in scope with the instantly claimed invention which does not recite the species “83A”. Amendment of the claims to recite the species argued, along with deposit of the strain to enable the claim, could obviate this rejection.

12. Merrill et al is asserted not to disclose a bacteriophage preparation having a wide host range.

13. It is the position of the examiner that the bacteriophages of Merrill et al are specific for a genus of bacteria which would include a plurality of species and strains (see claim 13, Merrill et al, col. 16, lines 34-39). In example 6, Merrill et al utilized lambda coliphages (see col. 14, line

Art Unit: 1645

48-49) which would specifically interact with multiple strains of Escherichia coli based upon the lambda receptor being present in E.coli.

14. Merrill et al is asserted to not teach a composition comprising two or more bacteriophage strains.

15. It is the position of the examiner that each strain of bacteriophage is not required to infect a different bacteria, but the strains must differ one from the other to be considered a separate strain of bacteriophage. The bacteriophage preparations are selected based upon serial passage of the bacteriophages through a host, thus producing a preparation of bacteriophages that represent at least two strains of spontaneous mutants that evidence delayed inactivation by the host defense system (see col. 5, lines 32-47). The isolated mutants (at least two strains) are grown to high titer and administered to an animal in need of treatment (see col. 5, lines 42-46). Merrill et al, through administering a full array of bacteriophages (see col. 7, line 1, Merrill et al), accomplishes like that of Applicant's claims, the administration of a single bacteriophage preparation containing a plurality of strains of bacteriophage that enables treatment.

It is also the position of the examiner that more than one process can be used to obtain the administered bacteriophage preparation with the recited functional limitations, one such process is disclosed by Merrill et al.

16. Merrill et al is traversed on the grounds that the preparation of Merrill et al is not purified and non-toxic phage preparation.

17. It is the position of the examiner that the bacteriophage preparation of Merrill et al is isolated and purified (see Merrill et al, coll. 16, line 27, claim 12) and non-toxic (see col. 15, lines 21-25,

Art Unit: 1645

the bacteriophage preparation prevented death, thus was non-toxic and effective to kill infecting bacteria) phage preparation. It was noted by the examiner that none of the claims recite any specific levels of toxin present in the preparation. Applicant's arguments are not commensurate in scope with the instantly claimed invention. The rejection of the claims is maintained for reasons of record.

18. The rejection of claims 23-24, 33-34, 37-38, 47-48 under 35 U.S.C. 102(b) as being anticipated by Norris (US Pat. 4,957,686) is asserted to not teach or disclose a "wide host range" preparation of bacteriophage.

19. It is the position of the examiner that the bacteriophage preparation of Norris comprises two or more strains of bacteriophage (mixtures) which are virulent (parasitic to bacteria) and selected against *S.sanguis* (Norris, claim 3), and virulent against bacteria normally present in the mouth (see Norris claim 3), specifically defined to include bacteriophages specific for *S.aureus* (Norris, col. 3, line 19), *S.mutans* and strains of *lactobacillus* (see col. 1, line 25 and col. 3, line 2).

The bacteriophage that would infect one strain of *S.sanguis*, would also infection another strain of *S.sanguis* with the same or equivalent receptor. In light of the definition of "wide host range" encompassing the embodiment of infecting two different strains of the same bacteria, the bacteriophage of Norris would function in the same or equivalent manner as now recited in the claims. While the bacteriophage of Norris are species specific (see col. 3, lines 28-30), the bacteriophage would infect a plurality of strains of a single species. The composition of Norris also contains two or more bacteriophages for parasitic bacteria of the mouth. Applicant's arguments are not commensurate in scope with the instantly claimed invention.

Art Unit: 1645

20. The rejection of claims 26 and 40 under 35 U.S.C. 103(a) as being unpatentable over Merrill et al in view of Denney (US Pat. 3,793,151) is traversed on the grounds that the “examiner has mistakenly equated Merrill et al’s disclosure regarding an LD50 dose of bacteria to mice with the concept of wide-host range phage in Applicant’s invention.

21. It is the position of the examiner that contrary to Applicant’s assertion, the examiner has not mistakenly equated Merrill et al’s disclosure regarding an LD50 dose of bacteria to mice with the concept of wide-host range phage in Applicant’s invention. Wide host range involves killing but does not require any specific percentage killing. The functional limitation with respect to an in vitro assay for bacteriophage killing, defines the ability of the bacteriophage to infect and to function as a lethal entity.

It is the position of the examiner that the claimed method recites a single methods step of “administering” a composition and does not require an in-vitro assay to be carried out, but the preparation must have the capability to function in an in vitro assay to kill 50% of the bacteria in that assay. Bacteriophage that are capable to providing protection in vivo through killing an LD₅₀ dosage of bacteria (the bacteriophages of Merrill et al, Example 6, col. 14 to col. 15; and col. 11, lines 64-67) , would also have the capability of functioning to kill 50% of the same bacteria in an in-vitro assay. Both assay measure killing and define the administered composition as one that is effective to provide protection through killing at least 50% of the bacteria, to include bacterial elimination (100% bacterial cell death).

22. It is asserted that and LD50 dose refers to bacteria and not to bacteriophage characteristics.

23. While the examiner agrees that LD50 defines a dose of bacteria able to kill 50% of the experimental subjects, it is also the position of the examiner that the bacteriophage preparation of

Art Unit: 1645

Merrill et al was functionally defined to be effective to prevent death of animals that had and LD50 dose of bacteria administered thereto. A bacteriophage that is defined to be functionally effective to kill a lethal dose of bacteria for 50% of the subjects, would evidence the functional capability to kill 50% of the bacteria in an in vitro assay as well.

24. Denny is asserted to not remedy the deficiencies of Merrill et al, specifically a wide host range bacteriophage for *Streptococcus pyogenes*.

25. It is the position of the examiner that Denny was cited to show a *S.pyogenes* specific phage (see Denny: col. 2, lines 56-66) that is able to infect any unencapsulated strain of *S.pyogenes*. Bacteriophage preparations specific for two or more strains of *S.pyogenes* that are unencapsulated would define a wide host range bacteriophage by Applicant's definition. The rejection is maintained for reasons of record.

26. The rejection of Claims 27 and 41 under 35 U.S.C. 103(a) as being unpatentable over Merrill et al in view of He et al (1992) is traversed on the grounds the He et al does not disclose a wide host range bacteriophage as defined by Applicant.

27. It is the position of the examiner that the instant specification defines a plurality of embodiments that define the meaning of the phrase "wide host range". As the claims broadly recite any of the provided definitions, and the fact that He et al does disclose wide host range bacteriophages (see page 591, Results section, phage O-I, lysed *Salmonella* subgenus strains I, II, IIIa and IIIb, last paragraph to greater than 50%; see page 592, col. 1, paragraph (vi), where phage "Sh" lysed both *Shigella* and *Ecoli* to greater than 50%; *C.freundii* phage ϕ I lysed 50.% of

Art Unit: 1645

Citrobacter cultures, specifically 3, 222 strains). Clearly He et al discloses a plurality of wide host range bacteriophages, to include bacteriophages for C.freundii (see Table 3, page 592).

28. The rejection of claims 28 and 42 under 35 U.S.C. 103(a) as being unpatentable over Merrill et al in view of Sekaninova et al (1995) is traversed on the grounds that Sekaninova et al is asserted not to remedy the deficiencies of Merrill et al and Sekaninova does not disclose a bacteriophage with a "wide host range".

29. It is the position of the examiner that the Merrill et al reference is not deficient as asserted (see discussion above), and Sekaninova et al showed 5 bacteriophages that were specific for Klebsiella oxytoca, as well as Klebsiella pneumoniae through teaching that the "biotypes of Klebsiella, i.e. K.pneumoniae and K.oxytoca, were identically sensitive to some of the phages 1, 2, 3, 8 and 106, particularly to phages 2 and 3". Thus the bacteriophages are disclosed to be "wide host range" bacteriophages for Klebsiella, to include specific for Klebsiella oxytoca (see abstract, last three lines). The bacteriophages are apart of the Polish Collection of Microorganism of the Polish Academy of Sciences, Wroclaw (see page 81, col. 1, paragraph 5, second sentence).

30. The rejection of claims 31 and 45 under 35 U.S.C. 103(a) as being unpatentable over Merrill et al in view of Bar-Shalom et al (US Pat. 5,213,808) is traversed on the grounds that the controlled release article of Bar-Shalom et al is not a liposome.

31. While the controlled release article of Bar-Shalom et al is not a liposome, the controlled release article of Bar-Shalom et al is taught to comprise liposomes that contain an active agent, the active agent being defined to include bacteriophages. Bar-Shalom et al (abstract, col. 9, lines 41-57; col. 9, lines 65-67 and col. 10, lines 1-3) shows liposomes for the purpose of delivering

Art Unit: 1645

an active agent to a mammal, wherein an active agent is a bacteriophage. The patent specifically teaches "the composition is in addition suitable for the delivery of"(col. 9, lines 41-42) "bacteriophages, e.g. as vaccines" (see col. 9, line 52). Bar-Shalom et al teaches the combination of vaccine bacteriophages incorporated in liposomes in the controlled delivery article.

32. The rejection of claims 45 under 35 U.S.C. 103(a) as being unpatentable over Merrill et al in view of Tomalia et al (US Pat. 5,714,166) is traversed on the grounds that a liposome and a dendrimer are not the same.

33. It is the position of the examiner that the Merrill et al reference is not deficient as asserted (see discussion above), and the dendrimers of Tomalia et al are not liposomes. The rejection of claim 31 has been removed. The combination of the two references teach the utilization of dendrimers as a carrier means for the delivery of high concentrations of a phage material (col. 1, lines 39-43; col. 47, lines 1-3) and the dendrimer of Tomalia provides a means for the controlled and targeted delivery of bacteriophage in a high concentration to a host. The rejection is maintained for reasons of record.

34. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ginny Portner whose telephone number is (703)308-7543. The examiner can normally be reached on Monday through Friday from 7:30 AM to 5:00 PM except for the first Friday of each two week period.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith, can be reached on (703) 308-3909. The fax phone number for this group is (703) 308-4242.


Art Unit: 1645

The Group and/or Art Unit location of your application in the PTO will be Group Art Unit 1645. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to this Art Unit.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Vgp

October 16, 2002



MARK NAVARRO
PRIMARY EXAMINER